Birgit Anderegg
Birgit Anderegg has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Christina Siefert
Department of Pathology Ludwig‐Maximilians University Munich D‐80337 Munich Germany
1 shared publicationDaniel W. Rosenberg
Center for Molecular Medicine, University of Connecticut Health Center, Farmington, Connecticut
1 shared publicationDoris Mayr
Department of Pathology, Ludwig-Maximilians University Munich, D-80337 Munich, Germany
1 shared publicationEvelyn Cheung
Arcturus Bioscience, Inc., Mountain View, California
1 shared publicationGudrun Amann
Department of Pathology Ludwig‐Maximilians University Munich D‐80337 Munich Germany
1 shared publicationJoachim Diebold
Department of Pathology Ludwig‐Maximilians University Munich D‐80337 Munich Germany
1 shared publication
Latest Publications
- 17 May 2004
- Published by Wiley in Cytometry Part A
- Vol. 59A (2) , 254-261
Microgenomics: Identification of new expression profiles via small and single‐cell sample analyses
Background Since the sequencing of the human genome has been finished, microgenomics has been booming, employing highly sophisticated, high‐throughput platforms. But these mainly chip‐based methods can only generate biologically relevant data if the samples investigated consist of homogenous cell populations, in which no unwanted cells of different specificity and/or developmental stage obscure the results. Methods Different sampling methods have been routinely applied to overcome the problem presented by heterogeneous samples, e.g., global surveys, cell cultures, and microdissection. Various methods of laser‐assisted microdissection, employing either positive or negative selection of tissue areas or even single cells, are available. Results These laser‐assisted microdissection methods allow for fast and precise procurement of extremely small samples. Through subsequent application of recently developed methods of linear mRNA amplification in a pool of isolated total RNA, it has now become possible to perform complex high‐throughput RNA expression profiling by microdissecting and processing even single‐cell samples. Conclusions Studies using the tools and methods of microgenomics have shed light on how those new approaches will eventually aid in the development of a new generation of diagnostics, e.g., leading to new patient‐specific drugs tailored to the requirements assessed by assaying only a few biopsy cells.
- 17 May 2004
- Published by Wiley in Cytometry Part A
- Vol. 59A (2) , 254-261
Microgenomics: Identification of new expression profiles via small and single‐cell sample analyses
Background Since the sequencing of the human genome has been finished, microgenomics has been booming, employing highly sophisticated, high‐throughput platforms. But these mainly chip‐based methods can only generate biologically relevant data if the samples investigated consist of homogenous cell populations, in which no unwanted cells of different specificity and/or developmental stage obscure the results. Methods Different sampling methods have been routinely applied to overcome the problem presented by heterogeneous samples, e.g., global surveys, cell cultures, and microdissection. Various methods of laser‐assisted microdissection, employing either positive or negative selection of tissue areas or even single cells, are available. Results These laser‐assisted microdissection methods allow for fast and precise procurement of extremely small samples. Through subsequent application of recently developed methods of linear mRNA amplification in a pool of isolated total RNA, it has now become possible to perform complex high‐throughput RNA expression profiling by microdissecting and processing even single‐cell samples. Conclusions Studies using the tools and methods of microgenomics have shed light on how those new approaches will eventually aid in the development of a new generation of diagnostics, e.g., leading to new patient‐specific drugs tailored to the requirements assessed by assaying only a few biopsy cells.
- Open Access
- 19 February 2003
- Published by Wiley in The FASEB Journal
- Vol. 17 (6) , 693-695
Does endometriosis really have premalignant potential? A clonal analysis of laser‐microdissected tissue
Since 1925, epidemiological and histological evidence for an association between endometriosis and ovarian neoplasia has accumulated. Recently, publications assaying the clonality of a given cell population have implied endometriosis has premalignant properties. However, the human androgen receptor used as a marker in these studies is of highly questionable reliability due to the instability of its methylation pattern in nonmalignant cells and during the course of malignancy. Therefore, we decided to readdress the question of clonality of endometriotic foci by using an alternative assay based on a polymorphism of the phosphoglycerate kinase‐1 gene. We overcame the limitation to using ovarian cysts (a problem encountered in other studies) by lasermicrodissecting defined tissue fractions of interest. From the 13/29 informative patients, a total of 32 endometriotic samples from various sites was assayed. Only 2/32 samples from different patients bore monoclonal tissue. With one of those cases, we present the first direct evidence of the two morphological endometric compartments comprising a single biphasic developmental unit. Neither monoclonal patient was characterized by any outstanding clinical parameters, including neoplasia. Individual endometriotic foci from the only patient in this study with neoplasia was assayed as being polyclonal. Therefore, former studies stating endometriosis as premalignant have to be cautiously reinterpreted.
- 19 February 2003
- Published by Wiley in The FASEB Journal
- Vol. 17 (6) , 693-695
Open AccessDoes endometriosis really have premalignant potential? A clonal analysis of laser‐microdissected tissue
Since 1925, epidemiological and histological evidence for an association between endometriosis and ovarian neoplasia has accumulated. Recently, publications assaying the clonality of a given cell population have implied endometriosis has premalignant properties. However, the human androgen receptor used as a marker in these studies is of highly questionable reliability due to the instability of its methylation pattern in nonmalignant cells and during the course of malignancy. Therefore, we decided to readdress the question of clonality of endometriotic foci by using an alternative assay based on a polymorphism of the phosphoglycerate kinase‐1 gene. We overcame the limitation to using ovarian cysts (a problem encountered in other studies) by lasermicrodissecting defined tissue fractions of interest. From the 13/29 informative patients, a total of 32 endometriotic samples from various sites was assayed. Only 2/32 samples from different patients bore monoclonal tissue. With one of those cases, we present the first direct evidence of the two morphological endometric compartments comprising a single biphasic developmental unit. Neither monoclonal patient was characterized by any outstanding clinical parameters, including neoplasia. Individual endometriotic foci from the only patient in this study with neoplasia was assayed as being polyclonal. Therefore, former studies stating endometriosis as premalignant have to be cautiously reinterpreted.